Scaffold hopping and bioisosteric design — replacing functional groups to improve potency, selectivity, metabolic stability, and oral bioavailability while retaining binding geometry
Before optimizing a lead compound, medicinal chemists dissect its structure to identify three classes of problems: binding liabilities (groups that interfere with selectivity or cause off-target toxicity), metabolic liabilities (groups metabolized too quickly or to toxic metabolites), and physical property liabilities (groups causing poor solubility, low permeability, or efflux). Bioisosteric replacement addresses all three while preserving the core pharmacophore.
A systematic liability assessment examines a lead compound at five levels:
1. PAINS (Pan-Assay Interference Compounds): • Rhodanines, catechols, quinones, Michael acceptors, thiol-reactive groups • Create false positives by assay interference (fluorescence, covalent protein modification) • Identified by SMARTS pattern matching: >480 filter patterns in PAINS database • Catechol in lead: o-quinone formation under oxidative conditions → non-specific protein alkylation
2. Metabolic soft spots (in vitro microsomal metabolism mapping): • Incubate with HLM + NADPH, quench at 0/15/30/60 min → LC-MS/MS parent disappearance • MS/MS fragmentation maps metabolite structure → identifies exact oxidation/glucuronidation site • Para-methyl: CYP3A4/2C9 oxidation → alcohol → aldehyde → carboxylic acid (potential acyl glucuronide toxicity) • Methoxyphenyl: O-demethylation by CYP2D6 → catechol (electrophile) or CYP3A4 → ring hydroxylation • N-methyl amide: N-dealkylation by MAO or CYP → secondary amine (reactive iminium)
3. Toxicophores (structural alerts for toxicity): • Anilines: N-hydroxylation → DNA-reactive nitrenium ion (carcinogenicity risk) • Aryl halides (chloro, bromo at electron-poor aromatic): oxidative arene epoxidation • Thioureas: hepatotoxicity via CYP450-mediated oxidation to reactive sulfoxide • Hydrazines: direct DNA alkylation at N7-guanine • Nitro groups: nitroreduction by gut bacteria → aromatic amine toxicity
4. hERG channel liability: • hERG (Kv11.1) potassium channel: basic nitrogen + aromatic ring + H-bond acceptor → high-affinity binding • TdP (Torsades de Pointes) arrhythmia risk at plasma concentrations achievable in patients • Lead hERG IC50 = 0.3 μM (in fluorescence polarization assay): too close to target IC50 • In silico hERG model (DeepHERG, hERG-AT) predicts liability from SMARTS features
5. Chemical instability: • Aldehydes: reactive toward proteins and DNA (Schiff base formation) • Boronic acids: hydrolysis in plasma, instability at acidic pH • β-lactams: hydrolytic instability unless protected (penicillin-binding proteins) • Esters: plasma esterases rapidly hydrolyze (t½ in plasma <10 min for phenyl esters)
SAR deconvolution — identifying pharmacophore vs. modifiable positions: • X-ray crystal structure of lead in target active site: identifies essential H-bond donors/acceptors • Alanine scan analog matrix: systematically delete each substituent → measure IC50 • COOH participates in salt bridge to Arg123 (essential), but pKa 4.5 limits permeable fraction at pH 7.4
The COOH→tetrazole replacement is the canonical success story of bioisosteric design: it preserves the acidic proton, the negative charge at physiological pH, and the H-bond donor/acceptor geometry — while dramatically improving metabolic stability and membrane permeability. This single change converted EXP7711 (a potent but metabolically labile COOH compound) into losartan, the blockbuster ARB antihypertensive that has treated hundreds of millions of patients worldwide.
Carboxylic acid properties and limitations: • pKa ~4.5: >99% ionized at pH 7.4 → charged form → low passive permeability • H-bond donor (OH) + 2 H-bond acceptors (C=O oxygens) in binding site interactions • Metabolic liability: β-oxidation removes 2-carbon units; glucuronidation of COOH → potentially reactive acyl glucuronide (MRP-transported, protein-reactive) • Classical bioisostere for COOH: sulfonic acid (SO₃H, pKa ~1, no membrane permeability), hydroxamic acid (pKa 8.1, different geometry), phosphonic acid (di-protic, different)
1H-Tetrazole bioisostere: • 5-membered ring: nitrogen atoms at 1,2,3,4 positions + carbon at 5 • Two tautomers: 1H and 2H tetrazole — rapid interconversion in solution • pKa 4.7–4.9: almost identical to COOH → same ionization state at all physiological pH values • Volume: 86 ų vs. 60 ų for COOH — slightly larger but isosteric in binding pocket • H-bond: NH (donor) + 3–4 lone pairs on N atoms (acceptors) — similar pattern to COOH but different geometry • NO β-oxidation: no carbonyl carbon for thioesterification → no CoA-linked β-oxidation • NO acyl glucuronide: no COOH → no UGT1A3/3A1/4A1 glucuronidation • Membrane permeability (Caco-2 A→B): losartan ~10 × higher than EXP7711
Synthesis of 5-substituted tetrazoles: • Ugi-TMSN₃ route: nitrile + TMSN₃ + [3+2] dipolar cycloaddition → tetrazole (Ugi, 1958) • ZnBr₂ catalyst: arylnitrile + NaN₃ → tetrazole (Dimroth conditions) • Modern: Bu₂SnO/MW: clean, fast, scalable; regioselective N1 vs N2 substitution controlled by conditions • Protecting groups: SEM, Bn, PMB for N1 vs. N2-selective alkylation
Other COOH bioisosteres: • Acylsulfonamide (NHSO₂R): pKa 3.5, excellent H-bond donor/acceptor, used in venetoclax • Hydroxamic acid (NHOH): pKa 8.1, chelates metals → HDAC inhibitors (vorinostat) • Phosphonic acid (PO₃H₂): very polar, poor permeability — used for intracellular prodrugs (tenofovir alafenamide) • Squaric acid monoamide: flat, high polarity, selective for certain binding pockets
Fluorine is the most electronegative element (χ=3.98), has nearly identical van der Waals radius to hydrogen (1.47 vs 1.20 Å), yet imparts dramatically different properties: it blocks metabolic oxidation, increases lipophilicity when attached directly to carbon, stabilizes conformations through gauche effects, strengthens H-bonds by polarizing adjacent NH/OH groups, and enables halogen bonding. Over 20% of all marketed drugs and >40% of new drugs contain fluorine. Understanding its precise effects enables rational fluorination strategy.
Fluorine substitution effects are position-dependent and require case-by-case analysis:
1. Metabolic protection: • Aromatic C-H → ArF: blocks CYP450 aromatic hydroxylation at that specific position • Aliphatic C-H → CHF₂ or CF₃: blocks α-hydroxylation (rate constant reduced 100-1000×) • Para-F on aniline: blocks para-hydroxylation → carcinogenicity risk abolished • BUT: CF₃ groups can be oxidatively defluorinated to CF₂H (by certain CYPs) • α-F carbanion stabilization: adjacent CF₃ increases pKa of neighboring CH → reduces enamine/iminium formation
2. Lipophilicity effects (context-dependent): • ArF (ring fluorine): +0.14 per F → increases logP (direct aromatic fluorine effect) • CHF₂ aliphatic: -0.22 per F → decreases logP (polar C-F reduces logP vs. CH₃) • CF₃: +1.07 per CF₃ → major lipophilicity increase (highly fluorinated carbon) • gem-difluoro cyclopropane: conformational restriction + lipophilicity tuning • Fluoroalkyl ether: intermediate effect; polar F near oxygen partially cancels
3. Conformational effects: • gauche F-F repulsion: dictates preferred dihedral in fluoroalkyl chains • α-fluoro carbonyl: F lone pair - carbonyl C=O electrostatic attraction locks conformation • 4-F proline: locks trans/cis amide bond ratio (important for peptide mimetics, amide bond conformation) • Fluorine gauche effect: vicinal C-F bonds prefer gauche over anti → forces protein-bound conformation
4. Halogen bonding (F, Cl, Br, I): • σ-hole on halogen: positive electrostatic potential at X terminus of C-X bond • Halogen bond: X···Y (Y = O, N, S, π) with 165–180° C-X···Y angle • Strength order: I > Br > Cl >> F (F σ-hole too small, rarely forms halogen bonds) • Cl is most common in drugs: balances lipophilicity and metabolic stability • Examples: CDK2, PIM-1, p38 MAPK: crystal structures show Cl halogen bonds to backbone C=O
5. CF₃ group — the power substituent: • +1.07 lipophilicity, strongly electron-withdrawing (Hammett σm = 0.43) • Increases binding affinity when in hydrophobic pocket: better van der Waals contact (larger volume) • Reduces basicity of adjacent amines (useful for hERG liability reduction) • Reduces CYP3A4 binding (less electron donation from ring) • Common positions: para-CF₃ on anilines (fluoxetine, riluzole, celecoxib CF₃)
Ring bioisosteric replacement (scaffold hopping) changes the central ring system while maintaining the spatial positions of key pharmacophore groups. Beyond improving ADMET properties, scaffold hopping is essential for intellectual property (IP) diversification — enabling new drug candidates around competitor patents. Modern AI-driven scaffold hopping tools (Schrödinger FEP+, Synthia, Fragment networks) have transformed this from an art to a data-driven science, identifying replacements that were previously invisible to manual inspection.
A. Benzene → Pyridine (most common ring bioisostere): • Replace benzene CH with C-N (N = sp2 pyridine nitrogen) • Effects: -0.7 logP per N (increases water solubility), H-bond acceptor added • Reduces aromatic stacking toxicity (cytotoxicity associated with planar large π-systems) • Pyridine N lone pair: can chelate metal ions in active sites (kinase DFG-out, metalloproteases) • Reduces hERG binding: basic amine is less stabilized near electron-withdrawing pyridine N • Reduces CYP inhibition: direct coordination of pyridine N to heme iron (inhibitor becomes a CYP substrate) • Synthesis: electrophilic C-H functionalization is possible on pyridine via halogenation + cross-coupling
B. Benzene → Thiophene: • 5-membered aromatic ring: positions 2,3 map onto benzene 1,2 (non-linear geometry) • +0.3 logP vs. benzene (sulfur increases lipophilicity) • Potential CYP-mediated thiophenyl sulfoxide/epoxide toxicity → need risk assessment • Used when rigid pharmacophore alignment requires 5-membered ring geometry • Example: tienilic acid (withdrawn) had thiophene → reactive sulfoxide → hepatotoxicity
C. Benzene → Indole: • Fused bicyclic: adds NH (H-bond donor) + maintains aromatic character • Excellent binding to tryptophan pockets (e.g., serotonin 5-HT₂, kinase back-pocket) • NH adds metabolic site (N-glucuronidation, N-oxidation) — may need N-alkylation to block • Increases MW by 39 Da; shifts molecular weight toward Ro5 boundary • Examples: serotonin receptor drugs (ondansetron, granisetron, sumatriptan)
D. Amide → Triazole (peptide bond bioisostere): • 1,2,3-triazole and 1,2,4-triazole used as amide/peptide bond replacements • Resists hydrolysis (peptidases); click chemistry synthesis (CuAAC) is trivial and selective • Geometry: 1,4-disubstituted 1,2,3-triazole mimics trans-amide (3.8 Å C1-C4 vs. 3.7 Å for trans-amide) • Triazole adds dipole moment (≈5 D) that mimics amide polarity • Applications: enzyme inhibitors where amide is quickly cleaved; cell-penetrating peptide mimetics
E. Phenyl → Pyrimidine / Pyrazine (diazines): • Pyrimidine: two N atoms at 1,3 — reduce logP by 1.2 vs. benzene • Used in kinase inhibitors for hydrogen bonding to hinge residues (EGFR, imatinib scaffold) • Pyrazine (1,4-N): symmetric — useful for symmetric binding sites • Both: reduce metabolic lability, improve solubility dramatically • Weak bases (pKa ~2–3) do not affect ionization at physiological pH
Controllable bioisostere libraries: • Schrödinger Ring Bioisostere tool: automated enumeration of all ring replacements maintaining pharmacophore vectors within 0.5 Å RMSD • MayaChem BioisostereLib: 700+ ring replacements with properties • Artificial intelligence: GNN trained on published ring replacements predicts Caco-2, metabolic stability improvement
ABBV-168, a JAK1 inhibitor developed by AbbVie, underwent a critical scaffold hop from benzothiazole to aminopyrimidine that simultaneously reduced CYP3A4 inhibition (IC50 >100 μM vs. 2 μM), improved aqueous solubility (>100 μg/mL vs. <1 μg/mL), and maintained potency (JAK1 IC50 2 nM). This single scaffold change accelerated the compound from clinical hold to IND submission in 6 months.
Modern drug discovery no longer optimizes for potency alone. Multi-parameter optimization (MPO) simultaneously tracks 6–8 physicochemical and ADMET properties against target windows, scored into a single weighted metric. The Pfizer MPO score (cLogP, MW, tPSA, HBD, pKa, LogD7.4) has become an industry standard for prioritizing compounds with the best chance of succeeding in clinical development. The final optimized compound in our campaign achieves MPO 5.2/6.0 — firmly in the clinical candidate zone.
The Pfizer MPO score (Wager et al. 2010, 2016) was developed from analysis of CNS drug attrition to identify structural features associated with successful clinical outcomes. It uses 6 parameters with desirability functions:
MPO parameter definitions and target ranges: 1. cLogP: desirability 1.0 if ≤3, 0 if ≥5, linear interpolation Rationale: high logP → protein binding, poor selectivity, CYP inhibition, hERG, IDT 2. cLogD (pH 7.4): desirability 1.0 if ≤2, 0 if ≥4, linear Rationale: ionized fraction at physiological pH reduces lipophilicity-mediated liabilities 3. MW: desirability 1.0 if ≤360 Da, 0 if ≥500 Da Rationale: large MW → reduced permeability, P-gp substrate, reduced oral absorption 4. tPSA: desirability 1.0 if ≥40 and ≤90 Ų, 0 if ≤20 or ≥120 Ų Rationale: CNS penetration requires tPSA <90; permeability requires >20 for GI absorption 5. HBD count: desirability 1.0 if ≤0.5, 0 if ≥3.5 (linear between) Rationale: >3 HBD → poor membrane permeability, efflux substrate 6. pKa of most basic center: desirability 1.0 if ≤8, 0 if ≥10 Rationale: basic pKa >8 → ionized at pH 7.4 → charged form → hERG risk, P-gp substrate
Final compound MPO calculation: • cLogP = 2.1 → score 0.95/1.0 • cLogD = 1.8 → score 1.0/1.0 • MW = 388 Da → score 0.85/1.0 • tPSA = 74 Ų → score 1.0/1.0 • HBD = 1 → score 0.75/1.0 (tetrazole NH) • pKa_base = 7.2 → score 0.65/1.0 (piperazine N) Total: 5.2/6.0 → clinical candidate quality
Beyond Ro5 for non-oral modalities: • Lipinski Ro5 now complemented by Ro3 (fragment-like), Ro4 (CNS), eRo5 (bRo5 for cyclic peptides) • bRo5 (beyond Ro5): MW 500–1000, logP 2–8, HBD ≤6, HBA ≤15 — macrocycles, stapled peptides • PO bioavailability prediction models: random forest on 1M compounds predicts F>50% with AUC 0.82
In vivo PK confirmation (rat cassette dosing): • Cassette (N-in-1) dosing: 5 compounds dosed together at 1 mg/kg IV /5 mg/kg PO to 3 rats • UHPLC-MS/MS quantification with compound-specific MRM transitions — simultaneous PK for all 5 • Final compound: AUC(po)/AUC(iv) = 68% (oral bioavailability), t½ = 9h (supports QD oral dosing), Cmax = 1.8 μg/mL (3× IC90 tumor) • Dose projection to human: allometric scaling (CLh,rat → human) predicts 20 mg QD oral dose achieves efficacious exposure, confirms path to Phase I
The compound series underwent precisely 234 synthesis cycles over 18 months, starting from a 180 nM HTS hit with F=12%. The final clinical candidate (prematurely named compound 142) required 12 simultaneous matched molecular pair (MMP) analyses to identify the winning combination of bioisosteric changes — a task impossible without computational chemistry and ADME automation. The entire lead optimization journey compressed what previously took 4 years into 18 months through parallel synthesis and automated ADMET profiling.